OpGen, Inc. (OPGN) News
Filter OPGN News Items
OPGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest OPGN News From Around the Web
Below are the latest news stories about OPGEN INC that investors may wish to consider to help them evaluate OPGN as an investment opportunity.
OpGen Reports Third Quarter 2023 Financial Results and Provides Business UpdateTotal revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022Implemented certain cash management initiatives, including restructuring U.S. operations by reducing headcount during the third quarter of 2023Signed preferred stock purchase agreement with a potential strategic investor in October 2023Entered into a warrant inducement agreement with an institutional investor in October 2023Subsidiaries Curetis G |
Why Is OpGen (OPGN) Stock Up 540% Today?OpGen stock is undergoing a massive rally on Thursday following as OPGN investors react to two pieces of news from the company! |
Why Is Phio Pharma (PHIO) Stock Down 35% Today?Phio Pharma stock is pulling back on Thursday after shares of PHIO underwent a massive rally on Wednesday with a preclinical trial update. |
Why Is Secoo (SECO) Stock Up 703% Today?Secoo stock is experiencing a massive rally on Thursday with heavy trading of SECO shares despite a lack of news from the company. |
Why Is Tempest Therapeutics (TPST) Stock Down 35% Today?Tempest Therapeutics stock is taking a beating on Thursday as shares of TPST retreat from a massive rally yesterday on clinical trial news! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayPre-market stock movers are a hot topic among traders on Thursday and we're offering all of the latest coverage this morning! |
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross ProceedsROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash (the “Existing Warrants”), wherein the investor agreed to exercise the Existing Warrants to pur |
ChatGPT Parent OpenAI Aims At Budget-Friendly AI Innovations, Novo Nordisk's Popular Diabetes Drug Ozempic Faces Counterfeit Threat in Germany: Today's Top StoriesBloomberg Apple and Suppliers Face Unanticipated Sales Slump Despite New Launches In a surprising turn of events, Apple Inc (NASDAQ: AAPL) and its key suppliers in Taiwan are facing a significant sales slump despite the recent launch of the new iPhone and various Android devices. Taiwan Semiconductor Manufacturing Co (NYSE: TSM), the leading contract chipmaker, experienced a 13.4% sales drop, a figure that, while concerning, is better than initially feared. Arm's Chinese Fortunes in Jeopardy? In |
Why Is Glimpse (VRAR) Stock Down 43% Today?Glimpse in the news Friday following the release of a mixed earnings report and plans to change focus. |
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 29% Today?Tonix Pharmaceuticals stock is taking a beating on Friday after the company revealed details of an offering for TNXP shares. |